Parallel Advisors, LLC Fate Therapeutics Inc Transaction History

Parallel Advisors, LLC

  • $4.18 Billion
  • Q3 2024

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

May 20, 2024
BUY
$4.76 - $6.59 $909 - $1,258
191 Added 124.03%
345 $1,000
Q2 2023

Aug 04, 2023
BUY
$4.76 - $6.59 $909 - $1,258
191 Added 124.03%
345 $1,000
Q1 2023

May 20, 2024
BUY
$4.24 - $11.12 $652 - $1,712
154 New
154 $0
Q1 2023

Apr 25, 2023
SELL
$4.24 - $11.12 $1,361 - $3,569
-321 Reduced 67.58%
154 $0
Q4 2022

Feb 03, 2023
BUY
$9.86 - $23.83 $2,267 - $5,480
230 Added 93.88%
475 $4,000
Q3 2022

Nov 10, 2022
BUY
$21.04 - $36.06 $1,241 - $2,127
59 Added 31.72%
245 $5,000
Q2 2022

Aug 01, 2022
BUY
$17.78 - $42.39 $1,582 - $3,772
89 Added 91.75%
186 $5,000
Q1 2022

Apr 28, 2022
SELL
$29.67 - $60.28 $741 - $1,507
-25 Reduced 20.49%
97 $4,000
Q4 2021

Jan 20, 2022
BUY
$47.84 - $64.34 $4,688 - $6,305
98 Added 408.33%
122 $7,000
Q3 2021

Nov 02, 2021
BUY
$59.27 - $95.73 $474 - $765
8 Added 50.0%
24 $1,000
Q2 2021

Aug 06, 2021
SELL
$67.25 - $92.52 $1,076 - $1,480
-16 Reduced 50.0%
16 $1,000
Q1 2021

Apr 23, 2021
BUY
$72.16 - $117.4 $1,443 - $2,348
20 Added 166.67%
32 $3,000
Q4 2020

Feb 02, 2021
BUY
$38.09 - $100.95 $457 - $1,211
12 New
12 $1,000
Q4 2019

Jan 30, 2020
SELL
$13.39 - $20.73 $1,017 - $1,575
-76 Closed
0 $0
Q2 2019

Aug 05, 2019
BUY
$15.61 - $20.44 $1,186 - $1,553
76 New
76 $2,000

Others Institutions Holding FATE

# of Institutions
175
Shares Held
115M
Call Options Held
53.7K
Put Options Held
9K
View Full List

About FATE THERAPEUTICS INC

FATE Quotes by TradingView
  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $260M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email